New gene and cell-based therapies for lung cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 21, Issue 5, 2000, Pages 463-472

  Batra, R K ^a   Sharma, S ^a   Dubinett, S M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene therapy; Immunotherapy; Lung cancer

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 7; PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; CANCER IMMUNOTHERAPY; CELL TRANSFORMATION; DENDRITIC CELL; GENE THERAPY; GENE TRANSFER; HUMAN; LUNG CANCER; PRIORITY JOURNAL; RETROVIRUS; REVIEW;

EID: 0033818687     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9455     Document Type: Review

References (124)

1. Cancer statistics by race and ethnicity
2. Chemotherapy for advanced nonsmall cell lung cancer: Past, present and furore
3. Molecular abnormalities in lung cancer
4. The biology, of lung cancer
5. Science, medicine, and the future. Lung cancer
6. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers
7. Oncogenic forms of p53 inhibit p53-regulated gene expression
8. p185neu expression in human lung adenocarcinomas predicts shortened survival
9. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
10. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53
11. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions
12. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
13. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect
14. p53 as a target for anti-cancer immunotherapy
15. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
16. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
17. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
18. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
19. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
20. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication
21. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
22. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
23. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA
24. Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC)
25. Similarity of protein encoded by the human c-erbB-2 gene to the epidermal growth factor receptor
26. Biologic consequences of over-expression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells
27. Targeted tumor killing via an intracellular antibody against erbB-2
28. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines
29. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous pl6 and Rb status in human cancer cells
30. bcl-2 Protein in non-small cell lung carcinoma
31. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
32. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
33. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants
34. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma
35. Granulocyte colony-stimulation factor (G-CSF) gene transfer suppress tumorigenicity of a murine adenocarcinoma in vivo
36. Interleukin-2 gene transduction into freshly isolated lung adenocarcinoma cells with adenoviral vectors
37. Paracrine cytokine adjuvants in cancer immunotherapy
38. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
39. Cancer immunotherapy of established tumors with IL-12: Effective delivery by genetically engineered fibroblasts
40. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
41. Interleukin-7 gene transfer in non-small cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity
42. Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma
43. Human IL-7: A novel T cell growth factor
44. Interleukin 7 is a T cell growth factor
45. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy
46. IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4
47. Down-regulation of macrophage transforming growth factor-ssmessenger RNA expression by interleukin-7
48. Down-regulation of murine fibrosarcoma transforming growth factor-β1 expression by interleukin 7
49. Intratumoral administration of adenoviral interleukin-7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication
50. Multi-component gene therapy vaccines for lung cancer: Effective eradication of established murine tumors in vivo with interleukin 7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo-activated dendritic cells
51. Human non-small cell lung cancer cells express a type 2 cytokine pattern
52. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
53. Induction of interferon γproduction by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers
54. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients
55. Regulation of human cytolytic lymphocyte responses by interleukin-12
56. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
57. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12
58. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
59. Recombinant IL-12 administration induces tumor regression in association with IFN-γproduction
60. Interleukin-12-mediated killer activity in lung cancer patients
61. HER2/neuderived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
62. Identification of human cancers deficient in antigen processing
63. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
64. Recent advances in the study of dendritic cells and follicular dendritic cells
65. The dendritic cell system and its role in immunogenicity
66. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
67. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
68. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced routine dendritic cells
69. Dendritic ceils augment granulocyte-macrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer
70. The host-tumor immune conflict: From immunosuppression to resistance and destruction
71. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production
72. Specific inhibition of cyclooxygenase 2 restores antitumor immunity by altering the balance of IL-10 and IL-12 synthesis
73. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice
74. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production: Role of tumor-derived IL-10, TGF-beta and prostaglandin E2
75. 2 enhance peripheral blood lymphocyte IL-10 transcription and protein production
76. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas
77. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy
78. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin (ogen) in lung neoplasms: An immunohistochemical study
79. Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism
80. Inhibition of invasion and metastatis in cells transfected with an inhibitor of metalloproteinases
81. Stromelysin-3 expression promotes tumor take in nude mice
82. Halting angiogenesis suppresses carcinoma cell invasion
83. Angiogenesis in cancer, vascular, rheumatoid and other disease
84. Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression
85. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
86. Endostatin: And endogenous inhibitor of angiogenesis and tumor growth
87. Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls
88. Chemokines and cell migration in secondary lymphoid organs
89. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer
90. The role of CXC chemokines in the regulation of angiogenesis in nonsmall cell lung cancer
91. Inhibition of Interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SC1D mice
92. Integrins: Versatility, modulation, and signaling in cell adhesion
93. Integrin b1- and b3-mediated endothelial cell migration is triggered through distinct signaling mechanisms
94. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
95. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
96. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
97. IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death
98. Selective enhancement be an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene
99. Radiotherapy for genes that cause cancer
100. Vitally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts
101. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity
102. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity
103. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer
104. The retroviral vector. Replication cycle and safety considerations for retrovirus-mediated gene therapy
105. Gene therapy
106. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
107. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
108. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
109. Transduction of non-small cell lung cancer cells by adenoviral and retroviral vectors
110. Diversity, of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer
111. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
112. Cellular and humoral immune responses to viral antigens create barriers to long-directed gene therapy with recombinant adenoviruses
113. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs
114. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector
115. Cyclophosphomide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung
116. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
117. Targeted gene delivery by tropism-modified adenoviral vectors
118. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types
119. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients
120. Phase I trial of recombinant adenovirus gene transfer in lung cancer: Longitudinal study of the immune responses to transgene and viral products
121. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patient with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
122. Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions
123. Transfer of genes to humans: Early lessons and obstacles to success
124. Barriers to drug delivery in solid tumors